THE MODERN THERAPY of hypertension began 35 years ago with the clinical trials of the first orally active drugs hydralazine and hexamethonium. Its success in reducing morbidity and mortality has been phenomenal. The efforts of the pharmaceutical industry have been extraordinarily successful, and from this small beginning in 1951 with two drugs representing two different mechanistic approaches, we now have over 40 drugs that can be divided into four broad classes -diuretics, adrenergic inhibitors, vasodilators (including calcium-entry blockers), and angiotensinconverting enzyme inhibitors. Each class has several different compounds, some with nearly identical structures and others with widely different configurations.
Rational therapies for hypertension
THE MODERN THERAPY of hypertension began 35 years ago with the clinical trials of the first orally active drugs hydralazine and hexamethonium. Its success in reducing morbidity and mortality has been phenomenal. The efforts of the pharmaceutical industry have been extraordinarily successful, and from this small beginning in 1951 with two drugs representing two different mechanistic approaches, we now have over 40 drugs that can be divided into four broad classes -diuretics, adrenergic inhibitors, vasodilators (including calcium-entry blockers), and angiotensinconverting enzyme inhibitors. Each class has several different compounds, some with nearly identical structures and others with widely different configurations.
With this bewildering array of drugs with many different mechanisms of action, it would be difficult for the general physician to use drugs with any degree of appropriateness as beginning treatment or to have alternative approaches if the original therapy is ineffective. This problem has been addressed by reports of the Joint National Committees on the Detection, Evaluation and Treatment of Hypertension (JNC I-III), which have provided the "stepped care" guidelines indicating drugs to use for first treatment and then alternative therapies as needed. These reports have been the mechanism whereby the National High Blood Pressure Education Program (NHBPEP) of the National Heart, Lung, and Blood Institute has fulfilled its mandate to bring recommendations for blood pressure control to U. S. physicians. They have been widely disseminated and are likely responsible for the accelerated decreases in death rates from complications of hypertension that have occurred since the program was established in 1972. Although death rates had fallen substantially in the 20 preceeding years, the success of the program is striking in that death rate from stroke decreased 42% in the first 10 years. Although deaths from myocardial infarction have fallen by 28%, there is no sure way to determine the role played by improved blood pressure control because hypertension is only one of the risk factors for coronary heart disease that has changed during this time.
In the meantime, new information concerning mechanisms of various stages and types of hypertension has been added to that already known in such an amount as to suggest that step 1 of stepped care is an archaic mode of therapy, that different types of hypertension should be treated more specifically, and that racial factors so influence responses to antihypertensive drugs that therapies appropriate for white hypertensives are apt to be ineffective for blacks with high blood pressure. This discussion will review that information and indicate alternative therapies to the most recent JNC III stepped-care guidelines. Its purpose is to focus on the evolving information about mechanisms of hypertension so that antihypertensive drug therapy can be chosen with greater specificity. It is not an attack on stepped-care use of more than one drug for good blood pressure control. Its emphasis is on step 1. Mild hypertension. The first report of the Hypertension, Detection and Follow-up Program drew attention to the frequency of mild hypertension. It divided hypertensives into three groups based on the height of diastolic pressure: mild, 90 to 104; moderate, 105 to 114; and severe 115 mm Hg or higher. Of the 168,000 people screened, over 10,000 were enrolled in the study and of these more than 70% had mild hypertension. The most recent report is that of the Subcommittee on Definition and Prevalence of JNC 111.2 Based on 1983 projections from national survey data, it estimates that 80% of Americans with a diastolic pressure of 90 mm Hg or higher have mild hypertension.
The implication of these data is that much of the hypertension that doctors treat is mildneither moderate nor severe. Which individuals among this group deserve pharmacologic therapy is a matter of continuing controversy. The JNC III report' clearly states that patients with diastolic pressures equal to or greater than 95 mm Hg deserve pharmacologic treatment be-cause that level of blood pressure is associated with shortened life span. For those 50 years of age or older with diastolic pressures of 90 to 94 mm Hg, a trial of nonpharmacologic therapy is recommended for several months with drug therapy later if weight reduction, salt restriction, and decreased alcohol intake fail to reduce diastolic pressure.
For those patients with diastolic pressures of 95 mm Hg or greater, JNC III recommends stepped care (figure 1). The first step is half a dose of either a diuretic or a /3-blocker with increase to full dose if the initial therapy is not effective, and it is estimated that well over half of all patients will respond to such treatment. It has been common clinical experience that mild hypertension is more responsive to single antihypertensive drug therapy than the more severe types.
This recommendation for starting therapy with a diuretic orS/-blocker is not based on sound pathophysiologic principles but is empiric in that these drugs often reduce arterial pressure in such patients and are well tolerated. For over two decades evidence has been accumulating that mild hypertension is often characterized by hyperdynamic circulation reflecting increased sympathetic activity apparently from brain centers. That evidence is of sufficient quantity and quality to suggest that rational therapy for mild hypertension is not stepped care but is one of a number of STEPPED CARE 1984 Begin with less than a full OR Begin with less than
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Add a vasodilator 3 * drugs that either reduce sympathetic vasomotor outflow or block adrenergic receptorsboth a and /3 types. Pathophysiology. The first suggestion for a neurogenic component in mild hypertension came with a 1967 report by Frohlich et al.3 of arterial pressure responses to head up tilt. Fifty-two hypertensive patients were studied who either had never received drugs or whose treatment had been discontinued for at least a month before the study. Of these, 24 had a normal blood pressure response to 5 min of a 50 degree tilt (mean arterial pressure + 10 mm Hg); 18 had orthostatic hypertension and 10 had orthostatic hypotension. The orthostatic hypertensives had the mildest hypertension of the three groups. They had high normal cardiac output when in the supine position that fell on tilt to the same degree as that of the normal responders but had a greatly exaggereated increase in total peripheral resistance on tilt. In addtion, they had an exaggerated pressor response to the Valsalva maneuver. Not only did the orthostatic hypertensives have milder hypertension than the other groups, but those who had been treated before had had good blood pressure control with drugs and most of them had received reserpine, since that was the drug usually used for therapy of mild hypertension in the late 1950s and early 1960s. It was these features that led to the report's conclusion that mild aful rs +| DUSTAN hypertension has a neurogenic component. Since then, ample supporting evidence has been developed.
Soon after Frohlich's original observation, the same group reported hemodynamic characteristics of various groups of hypertensives depending on the height of arterial pressure and evidence of vascular disease: borderline, mild, moderate, and severe hypertension. Hypertension was not classified only according to the height of arterial pressure as it now is, but the borderline category would be part of the group we now term mild hypertension.4 This study found borderline hypertension to be characterized by a modest elevation of cardiac output, stroke volume, and mean rate of left ventricular ejection. Later, Julius5 and others carefully delineated evidence that this hyperdynamic circulation reflects increased activity of the sympathetic nervous system. In addition, Julius has shown that the more rapid heart rate in patients with borderline hypertension is not only caused by increased sympathetic activity but also by deficient parasympathetic inhibition.
The implications of these hemodynamic and humoral characteristics of borderline hypertension have been summarized by Julius: "Borderline hypertension . . . presents a picture of multiple aberrations of the autonomic control of the circulation involving the vagus and the sympathetic discharge to alpha and beta receptors. Apparently, this abnormnality originates in higher integrative areas of the autonomic nervous control of the circulation."5
In addition to these hemodynamic characteristics, some mild hypertensives have been found to have increased plasma renin activity and plasma norepinephrine (PNE). The former has generally been considered to result from increased renal adrenergic nerve traffic and the latter from increased neurotransmitter release because of elevated sympathetic outflow from brain centers.
In 1969 Nestel6 reported that 40 min of mild mental stress (puzzle solving) administered to young normotensives and labile hypertensives raised arterial pressures and urinary excretions of norepinephrine and epinephrine more in the hypertensives than in the normotensive controls. More recently, Goldstein has reviewed the published studies of PNE in hypertension and found that only 41% reported significantly elevated concentrations compared with normotensive controls.7 PNE levels correlated positively with age in the normotensives but not in the hypertensives, whereas the hypertensive-normotensive differences were inversely related to age. This is significant because 64% of studies of patients less than 40 years of age were positive while only 18% were positive for patient 40 years of age or older. This review suggests that PNE levels will be higher in younger hypertensives and it is these people whose hemodynamic and humoral characteristics have been studied most thoroughly. Implications for therapy. The evidence for increased sympathetic neural activity in mild hypertension is compelling and required reconsideration of stepped care. In this context, diuretic therapy is empiric and treatment with /3-adrenergic blocking drugs is incomplete because they do not suppress a-adrenergic activity, which can intensify hypertension. Thus the drugs of choice for mild hypertension as beginning therapy are those that suppress sympathetic vasomotor outflow reserpine, methyldopa, clonidine, and guanabenzlabetalol or drugs that provide a-and /3-receptor blockade; at the present time labetalol is the only drug that fulfills this function. It should be remembered that the first suggestion of a neural component in mildborderline hypertension came from the study in which many patients had achieved good pressure control with reserpinenow rarely used but a very effective, cheap, centrally acting drug.
Goldstein et al. 8 have recently reported the value of a clonidine suppression test to identify patients who have increased sympathetic activity as a factor in their hypertension. They studied the relationship of the blood pressure fall 3 hr after administration of 0.3 mg of clonidine to resting PNE values and PNE at 3 hr after the drug. The magnitude of arterial pressure decrease was positively correlated with the baseline level of PNE and with the decrease in PNE after clonidine. They concluded that "this pattern of a relatively high resting level of plasma norepinephrine and a large fall in mean arterial pressure after clonidine appears to identify patients in whom excessive sympathetic neural activity contributes to their hypertension."8
The heterogeneity ofmild hypertension. The hemodynamic and humoral findings in mild-borderline hypertension are widely distributed. This is not surprising because even in the known types of hypertension (pheochromocytoma, primary aldosteronism, renovascular etc.) there is a broad range of hemodynamic and humoral values. Julius5 has found that about 30% of borderline hypertensives had significant elevation of cardiac output. This means that in the greater percentage of such hypertensives, the cardiac output being normal, the important hemodynamic abnormality is an elevated vascular resistance.
Thus this recommendation to use centrally acting aagonists or an a-c3-blocker as first-line therapy in mild hypertension may have relevance for only a fraction of those patients and at the present time we have no way 98 CIRCULATION of determining who they are. Perhaps, PNE concentrations may give a clue if the blood is drawn according to carefully detailed guidelines related to sodium intake, posture, stress of venipuncture, and so on. However, need for such careful control of the conditions of sampling would likely reduce the value of the test.
An intriguing possibility, however, is that all mildborderline hypertension has primarily a neurogenic mechanism regardless of the hemodynamic characteristics. This would mean that in some patients there is a predominant ,B-adrenergic hyperactivity, in others a predominant a-adrenergic mechanism, and in the rest a combination of both. There is ample evidence in experimental hypertension (dog, pig, rabbit) that a pressor stimulus can raise arterial pressure by elevating cardiac output or peripheral resistance or by evoking autoregulation with a change from elevated cardiac output to vasoconstriction.9
In my experience it is worthwhile to begin therapy of mild-borderline hypertension with a centrally acting antihypertensive drug or an a-f3-blocker. Serious consideration should also be given to reinstituting reserpine as therapy for such patients. Small doses are not associated with any more mental depression than is use of other centrally acting drugs, and the original reports concerning association of the drug with cancer were not substantiated in further studies. It is a safe, effective, and cheap therapy. Moreover, it can be given once a day.
Centrally acting drugs often cause fluid retention, although guanabenz has a lower potential to do so. Thus it is usually necessary to use a diuretic as step 2. Another problem with these agents is their side effects, particularly drowsiness and dry mouth, so we look forward to development of new drugs with similar mechanism of action but without those side effects.
Also, it seems likely that more a-f3-blockers will soon be available, although the current drug, labetalol, seems better tolerated than the centrally acting agents.
Hpertension in blacks. There is a growing body of evidence that antihypertensive drugs have a different spectrum of effectiveness in black hypertensives than they do in whites with elevated blood pressure. This is important to establish because it influences choice of therapy, which in itself is important because hypertension is more prevalent in blacks and more severe.
There is no evidence that black hypertensives have a different mechanism for their hypertension, at least as can be determined from hemodynamic and humoral characteristics.10 The hyporeninemia of hypertension in blacks has not yet been associated with a precise mechanism; low plasma renin activity is prevalent in Vol. 75, No. 1, January 1987 normotensive blacks as well as hypertensives and may be a racial characteristic relatively unimportant for hypertension. Thus the recommendations concerning different treatments for hypertension in black people come from assessing responses to antihypertensive drugs.
Responses to drug therapy. The Veterans Administration Cooperative Studies Program has investigated the responsiveness of black and white hypertensive men to hydrochlorothiazide, propranolol, and captopril. The propranolol-hydrochlorothiazide comparison was carried out in patients with diastolic pressures between 95 and 114 mm Hg;"1 683 patients (56.8% black) were followed during the dose titration phase of 10 weeks, and 394 of these (52% black) were enrolled in a maintenance phase that lasted for a year. In both the titration phase and long-term treatment, hydrochlorothiazide was more effective than propranolol in the black hypertensives. Whites had a better response to propranolol than blacks, although that drug was not as effective in them as hydrochlorothiazide.
This group has looked at racial differences in responses to captopril. 12 They found that white hypertensives had a better response than blacks to captopril alone. The addition of hydrochlorothiazide eliminated the racial difference and resulted in identical pressure averages in the two groups.
Implications for therapy. These results in a large number of patients support the findings in smaller groups and clearly establish the importance of diuretic therapy for hypertension in blacks. Thus it is recommended that for all but the most severe forms of hypertension, black patients first receive a trial of diuretic therapy.
Severe essential hypertension. Much progress has been made in the control of severe hypertension. During the early years of development of antihypertensive drugs, physicians had to be content with lowering supine diastolic pressure to 110 mm Hga level that was associated with control of progressive arteriolar disease and cardiac failure but would now be considered inadequate. Presently drugs are available for nearly routine reduction of diastolic pressure to less than 100 mm Hg. Good control is achievable through use of combination therapy and it is important to know what drugs are most useful and why they are chosen. Choices are based on the primary abnormality that characterizes severe essential hypertensionelevated vascular resistance.
Pathophysiology. Hemodynamic studies have described the changes that occur as the result of high diastolic pressure.3 Cardiac output is sometimes normal but often modestly decreased, mean rate of left ventricular ejection is slowed and total peripheral resistance is markedly elevated. Mostly there is no clear evidence of increased adrenergic activity except for a small group of patients with findings suggestive of increased cardioadrenergic drive in addition to their high vascular resistance."3 Implications for therapy. The approach to such problems is not step 1 of stepped care but a direct attack on arteriolar vasoconstriction through use of a potent vasodilator. Sublingual nifedipine has proved effective as initial therapy followed by oral nifedipine or minoxidil. The compensatory adrenergic activation that these drugs evoke can be controlled by addition of a /blocker or a centrally acting adrenergic inhibitor and the fluid retention caused by minoxidil can be controlled by use of a diuretic. The fluid retaining potential of minoxidil is notable and sometimes large doses of furosemide are required to control it.
The future for specific therapies. It seems likely that the new few years will see development of more specific therapies and recommendations on how best to use different types of drugs. The angiotensin-converting enzyme inhibitors are a case in point. As of now they are indicated therapy for renovascular hypertension, but their scope of usefulness for the broad range of essential hypertension has not been determined. As noted above, captopril was found by VA investigators to be effective in mild-to-moderate hypertension and there is a possibility that these drugs will prove to have a broad spectrum of effectiveness because the reninangiotensin system is widespread in body tissues other than the kidney (brain, vessel walls, etc.) that function in blood pressure control.
Hypertension in the elderly is another topic that will surely see clarification in the near future. Of particular concern is isolated systolic hypertension. The European Working Party study,"4 recently published, showed decrease in stroke mortality, and data from the NHLBI Systolic Hypertension in the Elderly study indicate that diuretics are particularly effective for blood pressure control. 15 Finally, the usefulness of calcium-channel blockers should soon be established. They influence a mechanism fundamental to the hypertensive process and we have yet to learn whether calcium flux in vascular smooth muscle is the final common pathway through which all pressor mechanisms act. My opinion is that this information will be forthcoming when we know more about the specifics of calcium transmembrane transport and intracellular actions in vascular smooth muscle. It seems likely that the current drugs are firstgeneration prototypes and that later drugs will be developed with specificity for the pathophysiology of vascular smooth muscle without causing reflexive increases in heart rate and cardiac output. This should be possible because angiotensin-converting enzyme inhibitors reduce arterial pressure through vasodilation but with such apparent specificity that there is no compensatory sympathetic stimulation.
